
LivaNova PLC LIVN
$ 58.91
-0.02%
Annual report 2025
added 02-25-2026
LivaNova PLC Total Assets 2011-2026 | LIVN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets LivaNova PLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.61 B | 2.51 B | 2.43 B | 2.29 B | 2.2 B | 2.41 B | 2.41 B | 2.55 B | 2.5 B | 2.34 B | 316 M | 294 M | 264 M | 212 M | 211 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.61 B | 211 M | 1.7 B |
Quarterly Total Assets LivaNova PLC
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.56 B | 2.51 B | 2.56 B | 2.51 B | - | 2.45 B | 2.46 B | 2.43 B | 2.33 B | 2.34 B | 2.29 B | 2.29 B | 2.21 B | - | 2.42 B | 2.2 B | 2.2 B | 2.4 B | 2.37 B | 2.4 B | 2.41 B | 2.5 B | 2.41 B | 2.41 B | 2.41 B | 2.41 B | 2.41 B | 2.55 B | 2.55 B | 2.55 B | 2.55 B | 2.5 B | 2.5 B | 2.5 B | 2.5 B | 2.34 B | 2.34 B | 2.34 B | 2.34 B | 2.56 B | 2.56 B | 2.56 B | 2.56 B | - | - | - | 294 M | - | - | - | 264 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.56 B | 264 M | 2.33 B |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 12.92 | -1.22 % | $ 1.75 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
Electromed
ELMD
|
53.8 M | $ 25.3 | 0.8 % | $ 214 M | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
EDAP TMS S.A.
EDAP
|
77.2 M | $ 3.32 | 0.3 % | $ 124 M | ||
|
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
97.7 M | $ 10.45 | 1.06 % | $ 296 M | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.63 | -1.29 % | $ 39.2 M | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.01 | 1.52 % | $ 1.22 M | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
IRIDEX Corporation
IRIX
|
29.2 M | $ 1.06 | 2.43 % | $ 18 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
132 M | - | - | $ 10.2 M | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 14.68 | 0.27 % | $ 344 M | ||
|
Butterfly Network
BFLY
|
256 M | $ 4.46 | -9.45 % | $ 944 M | ||
|
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
5.3 B | $ 89.55 | 1.99 % | $ 12.1 B | ||
|
Delcath Systems
DCTH
|
124 M | $ 10.23 | 0.2 % | $ 366 M | ||
|
PAVmed
PAVM
|
38.8 M | $ 8.54 | -4.32 % | $ 5.73 M | ||
|
Insulet Corporation
PODD
|
3.19 B | $ 168.16 | 5.07 % | $ 11.8 B | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 37.38 | 3.95 % | $ 1.16 B | ||
|
Inspire Medical Systems
INSP
|
907 M | $ 53.3 | -0.21 % | $ 1.57 B | ||
|
Integer Holdings Corporation
ITGR
|
3.41 B | $ 87.37 | 4.42 % | $ 3.03 B | ||
|
Sintx Technologies
SINT
|
9.51 M | $ 2.07 | 4.02 % | $ 5.74 M | ||
|
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 81.79 | 0.7 % | $ 47.8 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Stryker Corporation
SYK
|
47.8 B | $ 316.83 | 0.54 % | $ 121 B | ||
|
Tactile Systems Technology
TCMD
|
274 M | $ 22.39 | -0.49 % | $ 512 M | ||
|
TELA Bio
TELA
|
81.4 M | $ 0.89 | 3.5 % | $ 41.8 M | ||
|
LENSAR
LNSR
|
71.4 M | $ 5.39 | - | $ 64.5 M | ||
|
TransMedics Group
TMDX
|
1.07 B | $ 98.3 | -0.27 % | $ 3.34 B | ||
|
Tandem Diabetes Care
TNDM
|
881 M | $ 18.53 | 2.04 % | $ 1.26 B |